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SUMMARY  
Background: Venous thrombosis (VT) is among the leading causes of maternal mortality 
in countries with high standards of perinatal care; however the long-term outcomes of 
pregnancy-related VT are unknown. 
Aims: To assess the long-term prevalence of post-thrombotic syndrome (PTS), a 
frequently occurring chronic complication after deep vein thrombosis (DVT), to identify 
possible predictors for PTS, and to evaluate disease specific quality of life (QOL) after 
pregnancy-related DVT compared with a control group. We also aimed to assess the
mortality and incidence of cancer after VT in this population.
Materials and Methods: The Norwegian Patient Register and the Medical Birth Registry 
of Norway were used to identify cases of women with a first-ever pregnancy-related VT 
during 1990-2003 from 18 Norwegian hospitals. Women without VT matched for time of 
delivery were selected by the Medical Birth Registry as controls. All VTs were validated 
using the hospital medical records. Total 559 women with pregnancy-related VT and 
1229 controls were identified and were invited to answer a comprehensive questionnaire. 
313 cases and 353 controls met to participate in 2006. The questionnaire included self-
reported Villalta score for the assessment of PTS and the disease specific QOL instrument
VEINES-QOL/Sym. In 2012, the original study population of 1788 women was linked to 
the Norwegian Cause of Death Registry and the Cancer Registry of Norway.
Results: PTS was found in 42% of 204 women 3-16 years after a lower limb pregnancy-
related DVT. Proximal DVT when occurring postnatal was the most important predictor 
for PTS. Higher age and smoking were also independently associated with PTS. Women 
with DVT reported reduced disease specific QOL compared to controls. Ten cases (1.8%) 
and 7 controls (0.6%) died during 13 years of follow-up. Mortality was 3.0 times higher 
among cases compared to controls (hazard ratio 3.0, 95% confidence interval 1.1-7.9, 
P=0.024). The mortality among cases was also 19 times higher than among the age-
adjusted Norwegian female population the first year after VT (standardized mortality 
ratio (SMR) 18.8, 95% confidence interval 7.8-45.3), but thereafter the mortality was 
similar (SMR 0.9, 95% confidence interval 0.4-2.0). Fifteen cases (2.7%) and 13 controls 
(1.1%) were diagnosed with cancer after index pregnancy and subsequent cancer was 2.5 
times more frequent among cases (hazard ratio 2.5, 95% confidence interval 1.2-5.2, 
P=0.017). Cases did not have higher incidence of cancer when comparing with the age- 
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and sex-adjusted general population (standardized incidence ratio 1.0, 95% confidence 
interval 0.6-1.7).
Conclusions: PTS was a common long-term complication after pregnancy-related DVT 
affecting almost half of the women and disease specific QOL in this population was
reduced compared to a control group. Cases had significantly higher mortality and 
incidence of cancer than controls during 13 years of follow-up. When comparing with the 
age-adjusted Norwegian female population, mortality was increased only the first year 
after VT and incidence of cancer was similar.
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1. INTRODUCTION
Venous thrombosis (VT) is an abnormal blood clot that forms within a vein and may 
obstruct normal flow of venous blood and destruct vein valves. The blood clot or 
fragments of the clot can break off and follow the blood stream to the pulmonary 
circulation, which is commonly known as pulmonary embolism (PE) and which is 
sometimes fatal. Approximately two-thirds of symptomatic VTs present as deep vein 
thrombosis (DVT) in the lower limbs and one-third as PE, most often thought to originate 
from the lower limbs, including about 5% presenting with a concurrent DVT.1–3
Occasionally VT occur in other veins, such as the veins of the upper limbs, mesenterial 
veins, or cerebral sinus veins. The risk of VT during pregnancy is approximately 10-fold 
the risk of non-pregnant women of the same age.4 Despite increasing awareness and 
prophylactic measures, VT continues to be one of the leading causes of maternal 
mortality in countries with high standards of perinatal care,5 but little is known about the 
long-term outcomes after pregnancy-related VT and this is the main topic of this thesis. 
1.1. EPIDEMIOLOGY AND RISK FACTORS OF VENOUS THROMBOSIS 
VT is a multifactorial disorder that arises as a result of genetic and environmental factors 
that interact. In the Norwegian HUNT 2 study, that included residents of the Nord-
Trøndelag county aged 20 years and older, a triggering factor could not be identified in 
about 50% of the cases (commonly called idiopathic VT). Active cancer and recent 
surgery were the most important triggering factors for VT in this study, together with 
immobilization, trauma, pregnancy, puerperium, and the use of combined oral 
contraceptives (COCs).3 These findings were in general in line with results from other 
studies.6–8 Patients often have more than one triggering factor for VT.7,9 The incidence of 
VT in Western countries is approximately 1 per 1000 individuals per year and increases 
with age.3,10,11 VT occurs as often in men as in women, but women are overrepresented 
among patients younger than 45 years.1,3,10 This is probably due to the risk associated 
with pregnancy and the use of COCs containing estrogen, both well known risk factors 
for VT among fertile women. COCs increase the risk of VT about 2-6 fold compared to 
non-users.12–14 The natural history of untreated symptomatic VT is not well-known, but 
the randomized trial by Barritt and Jordan in 1960 showed that approximately 50% of the 
patients with PE who did not receive anticoagulation therapy had recurrence and half of 
these were fatal.15
13 
1.2. TREATMENT OF VENOUS THROMBOSIS 
Unfractionated heparin was first introduced as treatment for VT in 1938, becoming 
standard therapy along with the use of oral vitamin K antagonists (VKA) during the 
1960s.16 All anticoagulants can potentially cause severe bleedings (see section “1.5.3.3.
Bleeding”). Unfractionated heparin must been given parenterally. Both unfractionated 
heparin and VKA require regular laboratory monitoring of the anticoagulant effect. VKAs 
have numerous of food and drug interactions and a narrow range for safety and 
effectiveness. Studies on low molecular weight heparin (LMWH) were conducted  from 
the early 1980s17 and LMWH was introduced in Norway in the late 1980s. As LMWH 
can be given as body weight adjusted fixed doses without any need for monitoring, 
treatment of VT can be given outside hospital.16 Recently, oral direct inhibitors of either 
thrombin or factor Xa have been developed. These new oral anticoagulants (NOAC) can 
be given in fixed doses independent of body weight and essentially without need for 
monitoring.18 After proximal DVT elastic compression stockings (ECS) may reduce the 
incidence of the frequently occurring chronic complication post-thrombotic syndrome 
(PTS).19 Recently catheter-directed thrombolytic therapy (CDT) for proximal DVT was 
reported to reduce the frequency of PTS.20  
According to the current American College of Chest Physician’s (ACCP) guidelines (9th
edition 2012), an acute DVT or PE should be treated initially with subcutaneous LMWH 
for minimum five days in combination with oral VKA. LMWH can be discontinued when
the international normalized ratio (INR) has been in the therapeutic range (2.0-3.0) for at 
least 24 hours. Minimum duration of anticoagulation is three months. Therapy can be 
extended if the risk of recurrence is high (see section “1.5.3.2. Recurrent venous 
thrombosis”), but bleeding risk and preference of the patient should be taken into account. 
The rationale for treatment of VT is prevention of thrombus extension and embolization. 
Daily use of ECS on the affected limb is recommended for two years after a proximal 
DVT.21
1.3. PREGNANCY-RELATED VENOUS THROMBOSIS 
In countries with good perinatal care VT occurs in approximately 1 woman per 1000 
pregnancies.22–25 The risk of VT seems to be about equally distributed between the 
antenatal and postnatal period and is increased in all three trimesters.23,25–27 The risk of 
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postnatal VT is very high during the first weeks after delivery and then rapidly declines 
(Fig.1).
Fig.1 Numbers of VT per week during and early after pregnancy
From Jacobsen et al.25 (with permission)
DVT in lower limbs is the dominant presentation of VT during pregnancy, but the relative 
frequency of PE increases after delivery.25,28 During pregnancy, 80-90% of the DVTs 
affect the left lower limb.29,30 This might be explained by compression of the left common 
iliac vein by the growing uterus at the point where it is crossed by the right common iliac 
artery. Moreover, DVTs occurring during pregnancy predominantly affect the ileofemoral 
veins rather than the calf- and popliteal veins.25,26,30 Pregnancy induces major changes in 
the hemostatic system in a pro-thrombotic direction, an adaption that is likely to have 
developed to provide efficient hemostasis and to protect the pregnant woman from serious 
bleeding during delivery. Pregnancy may be considered a hypercoagulable state because 
of the increased levels of clotting factors (such as factors II, VII, VIII, IX, and XI) and 
reduction of natural anticoagulants (protein S).31,32 After delivery coagulation rapidly 
normalizes during the first postnatal weeks.33 In addition, pregnancy induces venous 
stasis that predisposes to VT; compression from the enlarged uterus reduces venous blood 
flow from the lower limbs and hormonal changes induce venous dilatation.34,35
Endothelial damage in the pelvic blood vessels may occur during vaginal delivery or 
Cesarean section and may contribute to the increased postnatal risk of VT.36 Table 1
summarizes clinical risk factors that may predispose to VT in pregnancy.23,26,37,38
15 
 
Table 1 Risk factors for pregnancy-related VT (modified from 25,39)
Risk factor Adjusted
odds ratio*
(95% CI)
Antenatal VT
Assisted reproductive technology 4.3 (2.0-9.4)
Spontaneous twins 2.6 (1.1-6.2)
Weight gain <7.0 kg 1.7 (1.1-2.6)
Pre-SUHJQDQF\%0,NJP2 – no immobilization 1.8 (1.3-2.4)
Pre-pregnancy BMI  <25 kg/m2 – combined with strict 
immobilization**
7.7 (3.2-19.0)
Pre-SUHJQDQF\%0,NJP2 – combined with strict 
immobilization**
62.3 (11.5-337)
Smoking (10-30 cigarettes/day prior to or during pregnancy) 2.1 (1.3-3.4)
Postnatal VT
Non-emergency Cesarean section 1.3 (0.7-1.2)
Emergency Cesarean section 2.7 (1.8-4.1)
Vaginal delivery complicated with postnatal infection*** 20.2 (6.4-63.5)
Cesarean section complicated with postnatal infection*** 6.2 (2.4-16.2)
Pre-pregnancy BMI  <25 kg/m2 – no immobilization 2.4 (1.7-3.3)
Pre-pregnancy BMI  <25 kg/m2 – combined with strict 
immobilization**
10.8 (4.0-28.8)
Pre-SUHJQDQF\%0,NJP2 – combined with strict 
immobilization**
40.1 (8.0-28.8)
3RVWSDUWXPKDHPRUUKDJHP/– no surgery£ 4.1 (2.3-7.3)
3RVWSDUWXPKDHPRUUKDJHP/– surgery£ 12.0 (3.9-36.9)
Intrauterine foetal growth restriction 3.8 (1.4-10.2)
Preeclampsia 3.1 (1.8-5.3)
Smoking (10-30 cigarettes/day prior to or during pregnancy) 3.4 (2.0-5.5)
*Adjusted for age, parity, smoking, weight gain, preeclampsia, foetal growth restriction, gestational 
diabetes, premature rupture of membranes, body mass index (BMI), immobilization, multiple pregnancy, 
method of conception, mode of delivery, postnatal infection, bleeding and surgery; **immobilization = strict 
bed-UHVW  ZHHN DQWHQDWDO ***postnatal infection = clinical symptoms/signs + fever + elevated WBC; 
£surgery = curettage, evacuation of haematoma, or re-operation after Cesarean. Adapted from Jacobsen et 
al. (with permission)40
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1.4. TREATMENT OF PREGNANCY-RELATED VENOUS THROMBOSIS 
According to the ACCP-guidelines, LMWH is recommended for the prevention and 
treatment of VT in pregnant women because LMWH does not pass the placenta and is 
safe for the fetus. In opposite, VKAs cross the placenta and have the potential to cause 
fetal bleeding and teratogenicity.41 The use of VKA or LMWH in postnatal women who 
are breastfeeding is safe.42 For women with acute VT during pregnancy, the minimum 
recommended duration of anticoagulant therapy is three months and should be continued 
for at least 6 weeks after delivery.43 Randomized controlled trials are mainly lacking as 
background for recommendations of treatment and prophylaxis for pregnancy-related VT. 
Guidelines are to a large extent based upon results from observational studies, indirect 
evidence from other populations and expert opinions. There is an urgent need for 
randomized controlled trials in different pregnancy-related settings to give better advices 
to these women. 
1.5.   LONG-TERM COMPLICATIONS AFTER VENOUS THROMBOSIS 
1.5.1. POST-THROMBOTIC SYNDROME  
The post-thrombotic syndrome (PTS) is a common chronic complication after DVT in the 
lower limbs. PTS is a clinical condition that comprises various degrees of pain, swelling, 
skin changes, varicose veins and sometimes overt ulcers in the limb previously affected 
by a DVT. PTS is associated with reduced QOL44 and considerable costs for the society.45
Any degree of PTS occurs in 20-50% of patients after a DVT, whereas severe PTS occurs 
in 5-10%.46,47 Symptoms are aggravated when the patient is standing or walking and 
improves when the limb is elevated. The clinical picture of PTS is non-specific and 
patients without a history of DVT in the actual limb can experience similar complaints 
after other diseases or trauma affecting the lower limbs. However, such chronic 
symptoms and signs in a patient with a previous objectively confirmed lower limb DVT 
are most likely due to PTS. Not to be forgotten, these patients are also at increased risk 
for recurrent DVT, and this must be ruled out if the symptoms and signs are acute and do 
not improve after rest.48 Regarding PTS following a pregnancy-related DVT, see section
“1.5.1.7. Post-thrombotic syndrome after pregnancy-related DVT.” 
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1.5.1.1. HISTORY OF POST-THROMBOTIC SYNDROME 
The American surgeon John Homans was probably the first to describe what was 
previously known as the postphlebitic syndrome in 1917; “symptoms of swelling, 
ulceration, and pain which followed extensive thrombosis in the deep veins of the lower 
limbs”.49 In contrast to the extensive documentation from clinical studies on local 
extension of DVT, embolization, and recurrent VT during the first months after an acute 
episode, the frequent long-term complication PTS has over the years received little 
attention from researchers, and among the numerous large trials that have evaluated the 
efficacy of various antithrombotic treatments for DVT, none have evaluated PTS as a pre-
specified or primary endpoint. This might be explained by the lack of a commonly 
accepted definition of PTS and that studies of PTS require longer follow-up. 
1.5.1.2. PATOPHYSIOLOGY OF POST-THROMBOTIC SYNDROME 
The patophysiologic mechanisms leading to PTS is not completely understood. It is 
suggested that persistent obstruction to blood flow caused by residual thrombosis and the 
development of venous valve incompetence due to activation of inflammation or scarring 
associated with the acute and resolving thrombus lead to ambulatory venous 
hypertension. Persistent venous hypertension may result in pain, swelling, 
hyperpigmentation and venous ulcers, i.e., the symptoms and signs of PTS.48
Nevertheless, patients with persistent vein abnormalities do not necessarily develop PTS
and vein abnormalities and venous dysfunction is not always detected in a patient with
PTS.50–52
1.5.1.3. DIAGNOSIS OF POST-THROMBOTIC SYNDROME 
There is so far no single objective test to diagnose the presence of PTS, and it is usually 
diagnosed on the basis of typical symptoms and signs in a limb previously affected by 
DVT.53 Many different definitions have been used, and to a great extent this is likely to 
explain the differences in reported prevalence across studies. The Villalta score, the 
CEAP (clinical, etiologic, anatomic, pathophysiologic) classification, and the Ginsberg 
measure have all been used to diagnose PTS as summarized in Table 2. In 2005, Kolbach 
et al compared different classifications of PTS. The Villalta score, the CEAP-
classification, the Ginsberg measure, and 3 other scoring systems were compared among 
124 patients with objectively confirmed DVT 3-9 years earlier. The presence of any PTS 
in DVT limbs varied from 30% to 66% between the different scoring systems and the 
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ability to discriminate between DVT and controls limbs differed substantially.54 The 
Ginsberg measure and the Villalta scale were also compared by Kahn et al; one year after 
an objectively diagnosed DVT, 37% of the patients had PTS according to the Villalta 
scale, but only 8.1% according to the Ginsberg measurement, and poor agreement was 
found between the two scores.55 The symptoms and signs for PTS may resemble those for 
acute and sub-acute DVT, and there is no consensus for the optimal time to diagnose 
PTS. In some studies the prevalence of PTS increased gradually from the first months to 
several years after the diagnosis of DVT,19,20,56 but in other studies the prevalence did not 
increase after the first 4-6 months.46,51,57 In a randomized controlled trial from our 
research group on the efficacy and safety of additional CDT in patients with high femoral 
and/or iliac vein DVT (the CaVenT study), the prevalence of PTS assessed by Villalta 
score after 24 months was 56% in the patients who had received conventional 
anticoagulant treatment compared to 41% in those getting additional CDT. In this study, 
no differences in PTS could be detected between the two groups after 6 months (32% 
versus 30%, P=0.77).20 In recent studies PTS has often been assessed only once from 4 
months to 2 years after an acute DVT in a lower limb.20,58,59
1.5.1.3.1. THE VILLALTA SCORE 
In 2008, the Control of Anticoagulation Subcommittee of International Society on 
Thrombosis and Haemostasis (ISTH) recommended use of the Villalta score (Table 3) to 
standardize the diagnosis and grading of PTS in clinical studies.53 This is hopefully a step 
towards improved reporting in studies on DVT outcomes. According to this score the 
patient grades the presence and severity of 5 symptoms (0-3 points) and the 
physician/nurse grades 6 clinical signs after examination of the lower limb (0-3 points).
The presence of a venous ulcer automatically grades PTS to the severe category. The 
Villalta score has now been widely used by various groups in clinical studies.19,20,46,60–62
Arguments for using the Villalta score as the standard measure of PTS in clinical studies 
were that both subjective symptoms and physical signs of PTS are included and rated, the 
measurement has been shown to be valid, responsive to clinical change, and acceptable 
for users, it can be reproduced between different raters, and the score can be used to sub-
classify PTS; PTS/no PTS, no/mild/moderate/severe PTS, or as a continuous outcome.53
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Table 2 Diagnostic instruments for post-thrombotic syndrome
PTS 
instrument
Criteria Made 
for PTS
Rates 
PTS
Villalta 
199463
5 symptoms
6 clinical signs (see Table 3)
Yes Yes
CEAP
199564,65
7 clinical classes according to clinical signs (0-6)*
Each clinical class subclassified according to
Etiology (congenital, primary, secondary)
Anatomy (superficial, deep, perforator veins)
Pathophysiology (reflux, obstruction, both)
No# No
Ginsberg66,67
2000&2001
Pain and swelling (made worse by standing/walking 
DQG UHOLHYHG E\ UHVWHOHYDWLRQ RI WKH OHJ RI  
PRQWKGXUDWLRQDQGPRQWKVDIWHU'97and
Valvular incompetence (pletysmography/Doppler)
Global rating questionnaire – assess changes over 
time
Yes No
C0: No visible or palpable signs of venous disease; C1: Telangiectasies or reticular veins; 
C2: Varicose veins; distinguished from reticular veins by a diameter of 3mm or more; C3:Edema; 
C4: Changes in skin and subcutaneous tissue secondary to chronic venous disease 
(C4a: Pigmentation or eczema or C4b: Lipodermatosclerosis or atrophie blanche); 
C5: Healed venous ulcer; C6:Active venous ulcer; 
* Many studies have utilized only the clinical part of the CEAP classification68,69
# tool for categorization of the whole spectrum of chronic venous diseases including complication after 
DVT (PTS).
Table 3 The Villalta score
Symptoms Clinical signs
Pain
Cramps
Heaviness
Paresthesia
Itching
Pretibial oedema
Skin induration
Hyper-pigmentation
Redness
Venous ectasia
Pain on calf compression
All symptoms and signs are scored from zero (absent) to three (severe) and summarized to produce a total 
VFRUHUDQJLQJIURP]HURWR$WRWDOVFRUHRISRLQWVFRUUHVSRQGVWRDQ\JUDGHRI376-14 points to 
PLOGPRGHUDWH376DQGSRLQWVRUWKHSUHVence of a venous ulcer to severe PTS. A score <5 indicates 
no PTS. Adapted from Villalta S et al.63
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1.5.1.4. PREDICTORS FOR POST-THROMBOTIC SYNDROME 
Defining the risk factors for PTS is an area of ongoing research. Several factors have 
consistently been shown to be associated with PTS in clinical studies, while others results 
are conflicting or remain to be confirmed (Table 4).
Table 4 Predictors for PTS
Established 
predictors
x Recurrent ipsilateral DVT46,56,61,70
x Iliofemoral DVT46,47,71,72
x Obesity46,47,61,73
Possible 
predictors
x Poor quality of oral anticoagulation with VKA (INR <2.0 the more 
than 50% of the time) the first months after DVT61,74
x Inflammatory- and coagulation markers (interleukin-6, intercellular 
adhesion molecule-1, CRP, D-dimer)58,69,70,75,76
x Persistent symptoms one month after DVT46
x Age and sex (conflicting results)46,47,51,71
x Residual obstruction and/or valvular reflux (conflicting results)50–
52,72
x Level of exercise after VT77,78
 
1.5.1.5. HOW TO PREVENT POST-THROMBOTIC SYNDROME 
As PTS is a complication of DVT in a lower limb, the best way to reduce its frequency is 
to prevent DVT. It is well known that there is room for improvement in adherence to 
current guidelines regarding primary prophylaxis for hospitalized patients at risk for 
VT.21,79,80 Unfortunately, about 50% of all VTs are unprovoked, i.e., no triggering factor 
can be identified, and hence they are not easily avoided. As a recurrent ipsilateral DVT is 
associated with PTS, it is likely that better secondary prophylaxis to reduce recurrence 
also will reduce the frequency of PTS, but prolonging treatment with VKA from six 
weeks to six months did not reduce prevalence of PTS the next 10 years in a randomized 
Swedish study.81
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Two randomized controlled trials have shown that use of elastic compression stockings 
(ECS) reduces the risk of PTS by approximately 50% after a proximal DVT.19,82 In both 
trials, knee-high ECS class II with compression at ankle level of 30-40 mmHg was worn
daily for two years. These studies were not blinded and did not include placebo stockings. 
A third study reported no difference in frequency of PTS between patients that used ECS 
20-30 mmHg and those using placebo stockings, but in this study the use of ECS was 
started not earlier than one year after proximal DVT.67 One recent study found that 
below-knee ECS is as efficient as thigh-length ECS, and that thigh-length ECS is less 
well tolerated.83 The Canadian SOX-trial, a multicenter, randomized, double-blind trial 
that compares two years wear of knee-length ECS against placebo stockings, have 
included 803 patients, but the final results are still pending. Primary outcome is 
prevalence of PTS after two years.58
Early removal of the thrombus is hypothesized to prevent valvular damage and thus 
prevent development to venous incompetence and PTS in patients with iliofemoral DVT. 
In the CaVenT study (see section “1.5.1.3 Diagnosis of PTS”), 209 patients were 
randomly assigned to conventional treatment with LMWH and VKA alone or 
conventional therapy with additional CDT with alteplase.20 After two years of follow-up, 
56% of the patients in the control group compared to 41% of patients allocated additional 
CDT presented with PTS (P=0.047). The difference in PTS corresponded to an absolute 
risk reduction of 15%, but CDT gave also a small additional risk of bleeding compared to 
the control group. Although additional studies regarding the role of CDT for the 
prevention of PTS are needed and currently ongoing,84 CDT should be considered in 
patients with a high proximal DVT and low risk of bleeding.20
There is weak evidence suggesting that treatment with LMWH instead of VKA the first 
months after the acute VT can reduce the frequency of PTS, but studies with longer 
follow-up and validated assessment of PTS are needed for confirmation.85 Poor quality of 
VKA treatment the first months after an acute DVT seems to be associated with PTS.61,74
As NOAC have been shown to be at least as effective as VKA in preventing recurrence of 
VT,86,87 NOAC or LMWH may improve quality of anticoagulation and hence perhaps 
reduce frequency of PTS.88,89
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1.5.1.6. TREATMENT OF POST-THROMBOTIC SYNDROME 
Currently, there is no identified curative treatment for PTS. ECSs are often recommended 
for symptom relief, but its benefit is not documented.67 In patients with severe PTS with 
complaints not relieved by ECS an intermittent compression device can be tried, but 
neither this is well documented.62 Venoactive medications (e.g. rutosides, defibrotide, and 
hidrosmin) are not recommended according to the current ACCP guidelines; the evidence 
for these compounds being limited and of low quality.21,90 Surgery is sometimes chosen 
as a therapeutic approach in moderate and severe PTS when symptoms are not relieved by 
ECS, but randomized controlled trials are lacking and evidence of success of surgery is 
scarce.91
1.5.1.7. PTS AFTER PREGNANCY-RELATED DVT 
We are not aware of more than four studies that have assessed the risk of PTS or 
persistent symptoms of the lower limb after a pregnancy-related DVT. These studies have 
included a limited number of patients and have employed different diagnostic tools for 
the diagnosis of PTS.92–95 These studies are all from Sweden and are summarized in Table 
5. Two additional studies have evaluated PTS in young women, but in these studies very 
few of the participants had DVT related to pregnancy.96,97   
1.5.2. CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION 
Chronic thromboembolic pulmonary hypertension (CTEPH) is a long-term complication 
that may develop after acute PE and is caused by incomplete resolution of the PE.
CTEPH is GHILQHG E\ DPHDQ SXOPRQDU\ DUWHU\ SUHVVXUH  mmHg at rest and a left 
ventricular end-diastolic pressure <15 mmHg, both measured invasively while 
undergoing right heart catheterization. In addition multiple chronic occlusive 
thrombi/emboli that persist in the elastic pulmonary arteries after at least three months on 
effective anticoagulation have to be present to distinguish CTEPH from other forms of 
pulmonary hypertension.98,99 More recent studies suggest that the prevalence of CTEPH is 
up to 4-5% in survivors of a first episode of acute PE and that this complication occurs 
within the first one or two years after the event.100,101
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1.5.3. OTHER LONG-TERM CONSEQUENCES AFTER VENOUS THROMBOSIS 
1.5.3.1. MORTALITY 
Data on mortality after VT are in general limited and estimates vary considerably. This 
can be explained by different populations in the studies, including selected age groups 
and various comorbidity; in particular cancer and cardiovascular diseases. Most studies 
do not include cases of VT diagnosed post mortem, but if VT diagnosed by autopsy was
included, the mortality rates would be influenced by the various autopsy rates in different 
countries. All these factors make it difficult to compare mortality between studies. In the 
Norwegian HUNT 2 study, the overall 30-days and one year case-fatality rate (the 
number of deaths from any cause after the event/the number of first VT events) after a 
first objectively verified VT in the total population in this area was 6.4% and 21.6%, 
respectively. The risk of dying was highest during the first months, after which it 
gradually approached the mortality in the general population.3 Cancer was the most 
frequent cause of death in this study, and that is in line with other studies.7,102 The 
mortality also seems to be increased in populations without cancer.3,103 Other data on 30-
days and one year case fatality rates vary from 10-30% 7,104 and 20-40%,103–105
respectively. In a study of young Austrian women VT did not reduce long-term survival 
after the initial phase.106 It is currently not known whether the increased mortality after 
VT is limited to the first months after VT,3 or persists for extended periods.103,104
Pregnancy-related VT accounts for about 0.5-1.2 deaths per 100000 deliveries and the 
majority of these deaths are caused by PE and occur postpartum.25,26,107 We are not aware 
of studies reporting on the 30-days case-fatality rate and long-term mortality after
pregnancy-related VT.
1.5.3.2. RECURRENT VENOUS THROMBOSIS 
10-30% of patients with first-time VT develop a recurrent episode within the first 5 years 
after discontinuing oral anticoagulation.108–110 The recurrence rate may be as high as 40% 
after 10 years.81 Patients with idiopathic VT or cancer related VT are at increased 
risk.102,108,109 Patients with VT precipitated by surgery have a low risk for recurrence, 
thrombophilia do not seem to predict recurrence, while male gender seems to increase the 
recurrence risk.102,108,109,111–113 The risk of recurrence after an episode of pregnancy-
related VT is not known. In women with a previous VT the risk of a pregnancy-related 
recurrence is substantial during the whole pregnancy unless prophylaxis is used.114
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1.5.3.3. BLEEDING 
Bleeding is an inherent complication associated with any anticoagulant treatment, 
especially at the start of treatment.115 After the first three to six months of treatment, long-
term anticoagulation with VKA targeted to INR 2.0-3.0 is associated with major 
bleedings of approximately 2% per year in patients with previous VT. About 10% of 
these major bleedings are fatal. Age >75 years, concomitant antiplatelet therapy, and 
previous bleeding are among the risk factors for bleeding on anticoagulation therapy.116–
118 The duration of anticoagulation treatment after VT should be a balance of the risk of 
recurrent VT with and without treatment, and the risk of treatment induced bleeding.116   
1.5.3.4. CANCER 
Patients with an episode of acute VT have a two to three times increased risk to develop
cancer, particularly during the first year after the VT. The increased risk is similar for 
cases with DVT and PE. The association between VT and cancer is particularly strong for 
primary cancers of the pancreas, ovaries and liver, in patients less than 60 years of age 
and those having recurrent VT.119–122 It is not known if the increased risk for cancer the 
first year after VT also applies to women who have experienced pregnancy-related VT. 
1.5.3.5. CARDIOVASCULAR DISEASE 
Patients with unprovoked VT are at higher risk for subsequent arterial cardiovascular 
disorders as compared to those with provoked VT and controls.123 The risk is highest the 
first year after the VT, but seems to persist for many years.124 The association between 
venous and arterial diseases could be explained by common risk factors, but results are 
diverging.125,126  
1.6. QUALITY OF LIFE 
In 1948 the World Health Organization (WHO) defined health to include physical, 
emotional, and social well-being in addition to absence of disease.127 Over the past 
decades the patient’s point of view has been recognized as increasingly important in 
clinical studies in addition to clinical and laboratory indicators of illness, especially in 
patients with cancer and chronic disorders.128,129
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A major problem in quality of life (QOL) research is the lack of a commonly accepted 
definition of QOL. WHO has not changed their definition of health since 1948. Many 
other definitions of health and QOL have been proposed, emphasizing components as 
happiness and satisfaction with life. Obviously, QOL means different things for different 
people. In health research we are often not interested in QOL in the broad sense, but only 
those aspects relevant for disease and treatment. To distinguish this from QOL in general, 
many investigators use the term health-related quality of life (HRQOL). Others prefer to 
use the term patient-reported outcomes (PROs).130,131 A PRO is any report coming 
directly from patients, without interpretation by physicians or relatives.132 It is generally 
accepted that QOL should be self-reported, multidimensional, and include at least three 
domains; physical, physiological, and social functioning. An overall question regarding 
general health or QOL should also be included.133 Non-patient based assessments, e.g., by 
proxy or health care personnel, are documented to be poor estimates of individual 
patients’ QOL.134,135 In the absence of any formal definition of QOL, all investigators 
should describe what they mean by QOL. Some questionnaires focus more on physical 
symptoms, and others more on the impact of the symptoms on psychological aspects or 
satisfaction with life. To be clinically useful, all QOL questionnaires should satisfy the 
basic psychometric properties validity, reliability, sensitivity, and responsiveness. These 
properties are defined in Table 6. Most QOL questionnaires used in Norway are translated 
from English, and translations should adhere to suggested guidelines.131
Table 6 Definitions of psychometric properties of QOL questionnaires131
x Validity The QOL questionnaire measures what it is intended to measure and 
that it is useful for its intended purpose
- Internal: the results are correct for the particular group of 
people being studied
- External: generalizability
x Reliability The ability to yield the same score each time a measure is 
administered
x Sensitivity The ability to detect differences between patients or groups of 
patients
x Responsiveness The ability of a measure to reflect underlying change when a patient 
improves or deteriorates
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1.6.1. QUALITY OF LIFE AFTER VENOUS THROMBOSIS 
Generic QOL questionnaires can be used across diseases and treatment groups and also 
among healthy individuals, and they enable comparison between different patient groups 
and the general population. The Short Form (SF)-36 is the most commonly used generic 
QOL questionnaire and normative data from the general population in many countries are 
available.136,137 Generic QOL questionnaires may not detect clinically important problems 
in a specific population with a chronic disease, e.g. chronic venous disease after DVT in a 
lower limb. Different disease-specific QOL questionnaires, which focus on a particular 
condition or disease, have been developed to capture aspects closely related to the disease 
of interest. Disease specific questionnaires are regarded as more sensitive than generic 
questionnaires to detect clinical relevant outcomes in the patient population of interest.138
Several disease specific instruments have been developed and validated for the use in 
DVT patients.44,68,139–148 One disease specific questionnaire has been developed for the 
assessment of QOL after PE.149  
Long-term QOL after DVT and PE have been shown to be reduced compared to 
population norms when using SF-36 as a generic QOL questionnaire.143,150 Beyth et al. 
found that symptoms in the affected leg six to eight years after the acute DVT compared 
to no symptoms was associated with worse QOL when using 19 items from SF-36.139
PTS is an important predictor for reduced QOL and patients with severe PTS seems to 
have worse QOL than those with mild to moderate PTS.44,142,147 One study found that
PTS had a negative impact on QOL when assessed by the disease specific questionnaire 
VEINES-QOL/Sym, but not by SF-36.142 In another study QOL was found to be poorer 
among patients with prior VT compared to patients having other forms of chronic venous 
disease.145  
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2. AIMS
Long-term outcomes after pregnancy-related VT are not known. The aims of the current 
thesis were: 
x To assess the prevalence of PTS 3-16 years after a first-time pregnancy-related
DVT of the lower limb and to identify possible predictors for PTS in this
population.
x To evaluate long-term disease specific QOL after pregnancy-related DVT and to
identify socioeconomic factors or comorbidity as predictors of reduced QOL.
x To assess short- and long-term mortality and incidence of cancer after pregnancy-
related DVT.
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3. MATERIALS AND METHODS
This thesis is a sub-study of the Venous thromboembolism In Pregnancy (VIP) study, 
which is a large epidemiological study on clinical, biochemical, and genetic risk factors 
of pregnancy-related VT.25 The VIP study started in 2004 and one thesis on clinical and 
epidemiological risk factors and one on intrauterine fetal death have been 
completed.151,152 In addition to the present project two more PhD projects are ongoing 
focusing on biological risk markers of VT and on QOL after intrauterine fetal death. Data 
from questionnaires completed in 2006 by a selection of cases and controls participating 
in the original VIP study was used in papers I and II. The original study population (both 
cases and controls) from the VIP study was linked to the Norwegian Cause of Death 
Registry and the Cancer Registry of Norway in paper III. I became involved in the project 
from September 2009, and hence was not involved in the design of the study or in the 
collection of the main data, but was responsible for linking the registries in 2012. 
3.1. STUDY POPULATION 
3.1.1. IDENTIFICATION OF CASES 
For the VIP study the Norwegian Patient Register retrospectively identified women with a 
first-time VT (i.e. DVT, PE, or DVT in other veins) during pregnancy or within the first 
12 weeks postpartum in 11 out of 19 counties (18  hospitals) in Norway during 1990 
through 2003 using selected ICD 8, ICD 9 or ICD 10 codes. The ICD codes used for the 
identification of cases is presented in Table 7.25 Additionally, women aged 16-50 years 
with a VT diagnosis in the registry without simultaneously having a registered ICD code 
corresponding to pregnancy was cross-checked for pregnancy-related discharge codes 9-
12 months before and after the VT code. The latter search identified some extra patients 
because pregnancy-related codes are not always added to the VT code when these women 
are discharged from hospital.
The source population comprised 377155 women with 613232 pregnancies during the 
study period. Additional cases were identified at three major Norwegian university 
hospitals (Ullevål in Oslo, Haukeland in Bergen, and St.Olavs in Trondheim) using the 
Medical Birth Registry of Norway. These three hospitals counted for 32% of the 
deliveries in the VIP study. In the Medical Birth Registry only antenatal cases were 
registered, and 3% of the cases were exclusively identified in this registry. The Medical 
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Birth Registry was not used to identify additional cases outside the three mentioned 
hospitals. One physician reviewed all medical records at the treating institutions and 
validated each case as a pregnancy-related first-time VT. Cases with questionable 
findings were reviewed by an experienced hematologist. DVT was diagnosed according 
to standard local operating procedures using compression or color Doppler 
ultrasonography or venography, whereas PE was diagnosed using high probability 
perfusion lung scanning, spiral computed tomography, magnetic resonance imaging, or 
pulmonary angiography.25,39 Cases with VT associated with miscarriage, induced 
abortion, or ectopic pregnancy terminated before gestational week 23 were excluded from 
the study. Clinical diagnoses with no confirmatory test or with undetermined results were 
not included. More than 50% of cases with VT indentified through the two registries 
could not be included in the study because of invalid diagnosis of VT (Figure 2). The 
reasons for an invalid VT diagnosis were mainly a previous diagnosis of VT (not an acute 
event in the actual pregnancy) or referral to hospital with a suspected VT which was not 
confirmed. 
3.1.2. IDENTIFICATION OF CONTROLS 
As possible controls the Norwegian Medical Birth Registry was used to select four
women who gave birth at one hospital (Oslo University Hospital, Ullevål) at the same 
time as one case. We utilized the two first listed women as controls. If their medical 
records were not retrievable, we included the third or fourth selection. In total 1230 
controls were identified. According to the medical records, one woman from the control 
group had been treated for VT before the index pregnancy and was excluded. The 
pregnancy leading to labor at the same time as for a case was defined as the index 
pregnancy for each control. The final control population comprised 1229 women naïve 
for VT at the time of their index pregnancy.25,39  
3.1.3. STUDY POPULATION FOR PAPERS I AND II 
The 559 cases and 1229 controls who could be reached were invited to the study and 
asked to answer a comprehensive questionnaire and to deliver a single blood sample in 
2006. Total 313 patients and 353 controls met to participate in the study in 2006 and all of 
them signed informed consent (Figure 3). These 666 women constituted the study
population for papers I and II in the present thesis. 
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Table 7 International classification of diseases codes related to pregnancy
ICD 8 Cerebral vein thrombosis
450 Pulmonary embolism 
Portal vein thrombosis 
Venous thrombosis 
Venous thrombosis in puerperium 
673 Pulmonary embolism during pregnancy and puerperium 
ICD 9 325 Phlebitis and thrombophlebitis of intracranial venous sinuses
415.1 Pulmonary embolism 
451 Venous thromboembolism 
452 Portal vein thrombosis 
453 Other vein thrombosis 
671.3, 4, 5, 9 Deep phlebothrombosis, antepartum, postpartum and other 
thrombosis during pregnancy 
673.2, 3 Obstetric blood clot embolism, puerperal pulmonary 
ICD 10 G08 Phlebitis and thrombophlebitis of intracranial venous sinouses
I26 Pulmonary embolism 
I80 Venous thromboembolism 
I 82 Other venous thrombosis 
O 22.3, 5, 8, 9 Venous complications in pregnancy 
O 87.1, 3, 9 Venous thromboembolism in puerperium 
O 88.2 Pulmonary embolism in puerperium 
From Jacobsen et al.25 (with permission) 
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Fig.2 Selection of cases from the Patient Register and the Medical Birth Registry
Adapted from Jacobsen et al.25,39 (with permission)
36 
 
Fig.3    Study population for papers I and II (the sub-study in 2006) 
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3.1.4. STUDY POPULATION FOR PAPER III 
In paper III the study population consisted of the whole original VIP population of 559
cases and 1229 controls. Only four controls declined to consent to the linking to the 
Norwegian Cause of Death Registry and the Cancer Registry of Norway. Linking these 
1784 women with the Norwegian National Population Register in June 2012 identified 
two cases and eleven controls who had emigrated from Norway before the index 
pregnancy even though they gave birth in a Norwegian hospital; these were excluded 
from the study (Fig 4).
Figure 4 Study population for paper III
3.2. COLLECTION OF DATA 
3.2.1. DATA FROM THE PARTICIPANTS’ MEDICAL RECORDS 
Cases and controls were identified at each of the 18 participating hospitals. A specific 
case report form was developed for the study. The medical records were retrieved and 
predefined information for cases and controls was collected and registered in the case 
report forms. The index pregnancy for cases was defined as the pregnancy in which the 
first lifetime VT occurred, and for controls, it was the pregnancy leading to labor at the 
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same time as matching cases. Date of inclusion in the study was date of delivery in the 
index pregnancy. Demographic information and detailed information regarding the index 
pregnancy was collected, as well as parity, previous and present health/comorbidity, 
weight, height, and smoking habits at the beginning of the index pregnancy. Body mass 
index (BMI) was calculated from weight and height, and overweight was classified 
according to the WoUOG +HDOWK 2UJDQL]DWLRQ GHILQLWLRQ %0,  NJP2). For cases, 
detailed information regarding the actual VT, including the type of diagnostic 
verification, type of VT (i.e. DVT, PE, DVT+PE, DVT in other locations), extension of 
the thrombus, and lateralization was recorded. A proximal DVT in a lower limb was 
defined as a DVT at or above popliteal vein, possibly extending up to the iliac vein. A 
distal DVT included only the calf veins, i.e., below the popliteal vein. All cases of 
combined symptomatic DVT in a lower limb and PE were categorized in the analyses as 
DVT. These data from the case report forms are the basis for the predictor analyses in 
paper I and are used for description of the population in papers I and III.
3.2.2. QUESTIONNAIRE DATA FROM 2006 
In 2006 the 666 participants of the VIP sub-study met to answer a comprehensive 
questionnaire at their local hospitals after giving informed consent. The whole 
questionnaire was self-completed, but health personnel were present to answer any 
question if necessary. The questions concerned socio-demographic factors, obstetrical 
history, history on VT, general health, use of medication and contact with health 
personnel the last 12 months, self-reported Villalta score to assess PTS, one disease 
specific QOL questionnaire (the VEINES-QOL/Sym), and two different generic QOL 
questionnaires (Ferrans and Powers QOL Index and the General Health Questionnaire 
20). The questionnaire data were used to assess PTS and QOL in papers I and II and were 
also the basis for the predictor analyses for QOL in paper II. Questionnaire data were not 
used in paper III.
3.2.2.1. ASSESSMENT OF POST-THROMBOTIC SYNDROME 
In paper I we utilized a self-reported Villalta score, modified from the original Villalta 
score (Table 3), to diagnose and grade PTS. The self-reported Villalta score included the 
same 11 items as in the original, but all were completed by the patient herself. No health 
personnel were involved in the scoring, but a nurse was present when completing the 
questionnaire to answer questions if necessary. Each item in the self-reported Villalta 
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score was scored from zero (no complaints) to three (severe complaints) as in the original 
Villalta score and we defined any PTS as self-UHSRUWHG9LOODOWDVFRUHDQGVHYHUH376
as DVFRUH15 in a lower limb with a previous DVT. A question regarding the presence of 
a venous ulcer was not included. The self-reported Villalta score in Norwegian is 
included in the appendix of this thesis, and the version translated to English is available 
online as a supplemental file for paper I.
3.2.2.2. ASSESSMENT OF DISEASE SPECIFIC QUALITY OF LIFE 
The Venous Insufficiency Epidemiologic and Economic Study (VEINES) – quality of life 
(QOL) and symptoms (Sym) questionnaire was used to assess disease specific QOL in 
papers I and II. The VEINES-QOL/Sym questionnaire is the most frequently used 
disease-specific QOL questionnaire for DVT in the lower limbs. It was modeled after SF-
36 and comprises 26 items regarding leg problems. Items regarding symptoms, 
limitations in daily activity and psychological impact during the previous 4 weeks are 
included. Two summary scores are computed. The VEINES-QOL summary score 
assesses QOL, and the VEINES-Sym score measures symptom severity; higher scores 
represent better QOL and/or fewer symptoms. One item concerns the time of day of 
greatest symptom intensity and one covers change over the past year. These two items are 
not included in the summary scores.153 The VEINES-QOL/Sym questionnaire is validated 
in Norwegian and have been used in two Norwegian studies in addition to the VIP study 
(the QOL results from the CaVenT study are not published yet).148,154,155 The Norwegian 
version of the VEINES-QOL/Sym questionnaire is included in the appendix of this thesis.
The English version is included in the paper “Evaluation of outcomes in chronic venous
disorders of the leg: Development of a scientifically rigorous, patient-reported measure of
symptoms and quality of life” by Lamping et al.153
3.2.3. BLOOD SAMPLING AND ANALYSIS 
At the same time as completing the questionnaires and signing informed consent in 2006, 
all 666 study participants also donated a single blood sample. The handling of the blood 
samples is described in a previous publication.156 In paper I, we investigated on the role 
of  factor V Leiden (F5 rs6025) and the prothrombin gene G20210A (F2 rs1799963)
polymorphisms, and plasma D-dimer level (assayed using Asserachrom D-Dimer kit from 
Stago, Asnière, France) as possible predictors for PTS. The cut-off level for D-dimer was 
0.4 ȝg/L.
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3.3. STATISTICS 
All statistical analyses were performed using the Statistical Package for Social Science 
version 18.0 (SPSS Inc, Chicago, IL, USA) or Stata 12 (StataCorp LP, College Station, 
TX, USA). Findings with P-values below 0.05 were considered statistically significant.
Descriptive statistics were used to present the characteristics of the study population in all 
three papers, presented as frequencies, n (%), medians and means together with standard 
deviation (SD) or 95% confidence interval (CI). A two-sample t-test was used to compare 
two continuous variables if their distribution was close to normal; otherwise, a non-
parametric test (Mann-Whitney) was used. A two-sided chi-square test was used to 
compare dichotomous variables, but a Fisher’s exact test was used in situations where the 
expected counts of events or nonevents were less than five. When adjusting for possible 
confounders, linear or logistic regression was used depending of a continuous or a 
dichotomous variable of interest (dependent variable). When the dependent variable was 
continuous, but deviated extensively from the normal distribution, a logarithmic 
transformation of the variable was used in the regression analysis.  
Papers I and II: In both papers the variable of interest was dichotomized, i.e., PTS versus 
no PTS in paper I and VEINES score <25th percentile versus scores t50th percentile in 
paper II. We performed bivariate and multivariate logistic regression analyses to identify 
possible predictors for PTS and for reduced disease specific QOL. Backward variable 
selection was used to make the final model of predictors and the results were presented as 
odds ratios (OR) and adjusted OR with 95% CI. Possible interactions were checked. In 
papers I and II we computed the scores for the VEINES-QOL and VEINES-Sym using 
standard scoring algorithms obtained from Donna Lamping, London, United Kingdom.153
For computing the self-reported Villalta score for each patient with previous pregnancy-
related DVT in a lower limb, the points (0-3) for each of the 11 questions were just 
added. For the eight cases with no information on which limb was affected, we used the 
highest score of the two limbs and we did the same for cases with PE. We used the mean 
score for both legs when assessing self-reported Villalta scores among controls.  
Paper III: The frequency of comorbidity before index pregnancy was very low for both 
cases and controls, and when the expected counts of different diseases were less than five, 
we performed a Fisher mid-p test instead of the Fisher’s exact test when comparing 
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comorbidity between the two groups.157 Cox regression was used to calculate crude 
hazard ratios (HR) for mortality and cancer, with 95% CI, for cases compared with 
controls and to identify possible confounders for the association between VT and death or 
cancer. The observed mortality and incidence of cancer in our cohort was compared to the 
expected total mortality and incidence of cancer in the general Norwegian female 
population adjusted for age to obtain standardized mortality ratio (SMR) and standardized 
incidence ratio (SIR) for cancer. The statistics Norway158 and the Cancer Registry of 
Norway159 provided tables on the mortality and incidence of cancer in different age 
groups stratified for sex per 100000 inhabitants per year. A SMR/SIR above 1.0 means 
that the cohort has a higher mortality or incidence of cancer than observed in the sex- and 
age- matched Norwegian population, less than 1.0 means lower incidence than expected.
3.4. POWER ANALYSIS 
The VIP study was originally designed to identify clinical risk factors and possible 
biomarkers for pregnancy-related VT and power-analysis was performed to estimate the 
sample size needed for the VIP study. Power-analysis was not done for PTS/QOL until 
writing papers I and II. 
In paper III, we intended to identify mortality and incidence of cancer after pregnancy-
related VT. The complete study population of 559 cases and 1229 controls was planned 
linked to the Norwegian Cause of Death Registry and the Cancer Registry of Norway.
Using data from Statistics Norway we expected that 1.3% of the controls would have died 
from the time of the index pregnancy until linking. We assumed it was realistic that 3.5% 
of the cases had died in the same period and this would give a statistical power of 80%. 
We also assumed that the incidence of cancer among the controls during the follow-up 
period was approximately 1.4% (personal communication, senior researcher Steinar 
Tretli, the Cancer Registry of Norway). Using a two-sided chi-square test and a 
significance level of 5%, we were able to show that a cancer incidence of 4.0% among 
cases during follow-up, which we considered to be a realistic estimate, would make the 
power of this part of the study to be 90%. This power analysis was included when we 
applied the Southeastern Regional Committee for Research Ethics for permission to 
conduct the sub-study.
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3.5. RECOMMENDATIONS AND PERMISSIONS 
The project was approved by the Southeastern Regional Committee for Research Ethics 
(REK), the Norwegian Data Inspectorate, and the Norwegian Ministry of Health and 
Social Affairs. The study is registered at ClinicalTrials.gov with the unique identifier 
NCT 00856076. The project was in line with commonly accepted ethical principles. 
Informed consent was obtained from the 313 cases and 353 controls before they answered 
the comprehensive questionnaire. Letters of information were sent to a all the 1788 
women in 2011 and the linking with the Cancer Registry of Norway and the Norwegian 
Cause of Death Registry was done after passive informed consent as approved by REK,
and only four women actively declined to be included in the linkage studies. The studies 
were only descriptive and did not include randomization or treatment. The 
implementation of the project was not likely to cause any harm because the project was 
only descriptive.
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4. SUMMARY OF RESULTS
4.1. PAPER  I 
Prevalence and predictors for post-thrombotic syndrome three to 16 years after 
pregnancy-related venous thrombosis: a population-based, cross-sectional, case-
control study. Wik HS, Jacobsen AF, Sandvik L, Sandset PM. Journal of Thrombosis 
and Haemostasis 2012 May; 10:840-7.
In this paper we assessed the prevalence of PTS using self-reported Villalta score after a 
first-ever DVT during pregnancy or the first 12 weeks after delivery. Mean follow-up was 
9.1 years. 204 women with a previous DVT, 70 with PE only, and 349 controls completed 
the self-reported Villalta score. Forty-two % had PTS after DVT, and 24% of those with 
PE and 10% of controls also had a self-reported Villalta score of five or more. The total 
scores after DVT and PE were significantly higher than for controls, also when adjusted 
for possible confounders (P< 0.001 and P=0.025, respectively). A proximal DVT 
occurring after delivery was the strongest predictor for PTS, but also smoking and higher 
age were independently associated with PTS.
4.2. PAPER  II 
Long-term quality of life after pregnancy-related deep vein thrombosis and the 
influence of socioeconomic factors and comorbidity. Wik HS, Enden TR, Jacobsen AF, 
Sandset PM. Journal of Thrombosis and Haemostasis 2011; 9: 1931–6.
In this paper we assessed disease specific QOL and symptom severity in 208 patients with 
previous first-ever pregnancy-related DVT in a lower limb after a mean follow-up of 9.5
years compared with 347 controls consisting of women naïve for VT at the time of index 
pregnancy. The VEINES-QOL/Sym questionnaire was used to assess QOL and 
symptoms. Mean scores for VEINES-QOL were 45.6 (SD 12.4) for cases and 52.8 (SD 
7.0) for controls, and mean VEINES-Sym scores were 45.4 (SD 12.0) and 52.7 (SD 7.4).
Both scores differed statistically significant between cases and controls (P<0.001). We 
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defined a score <25th percentile as a clinically relevant reduced outcome compared to a 
VFRUH th percentile. Cases had poorer outcomes regarding both QOL and symptoms
compared to controls, also when adjusted for possible confounders. Adjusted OR for 
reduced QOL and more symptoms among cases compared with controls were 5.0 (95% 
CI 2.8-9.1, P<0.001) and 5.9 (95% CI 3.2-10.8, P<0.001), respectively. Low education 
was the only socioeconomic parameter to independently predict both reduced QOL and 
increased symptom scores among cases. 
 
4.3. PAPER  III 
Long-term mortality and incidence of cancer after pregnancy-related venous 
thrombosis: results of a population-based cohort study. Wik HS, Jacobsen AF,
Fagerland MW, Sandvik L, Sandset PM. Submitted.
In this paper we assessed mortality and incidence of cancer after VT in 557 women with 
pregnancy-related VT during 1990-2003 (cases) and 1214 controls without VT at the time 
of index pregnancy during a mean follow-up of 13.0 years. The Norwegian Cause of 
Death Registry and the Cancer Registry of Norway provided data on deaths and 
diagnoses of cancer. Ten cases (1.8%) and 7 controls (0.6%) died from any cause during 
follow-up. Mortality was 3.0 times higher among cases compared with controls (HR 3.0, 
95% CI 1.1-7.9, P=0.024). Mortality among cases was also significantly higher than 
among the sex- and age- adjusted Norwegian population the first year after VT (SMR 
18.8, 95% CI 7.8-45.3), but thereafter the mortality was comparable (SMR 0.9, 95% CI 
0.4-2.0). Fifteen cases (2.7%) and 13 controls (0.4%) were diagnosed with cancer after 
index pregnancy. The incidence of cancer was 2.5 higher among cases compared with 
controls (HR 2.5, 95% CI 1.2-5.2, P=0.017). Cases had similar incidence of cancer after 
VT as the sex-and age- adjusted Norwegian population (SIR 1.0, 95% CI 0.6-1.7).
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5. DISCUSSION
5.1. METHODOLOGICAL CONSIDERATIONS 
5.1.1. STUDY POPULATION 
5.1.1.1. SELECTION OF CASES FOR THE VIP STUDY 
Due to the strict validation criteria used it is likely that all identified cases actually had a 
pregnancy-related VT. Almost 50% of the patients that were identified in the registries 
proved not to have VT and were thus not included in the study, revealing the weakness of 
research based on hospital discharge codes only without validation. On the other hand, we 
cannot exclude that there may have been underreporting of cases. The Medical Birth 
Registry was only used to identify cases at the three large hospitals. Cases with inaccurate 
ICD coding at discharge from hospital, with missing medical records (n=53, Fig.2), or 
women who died from a pregnancy-related VT outside hospital were not included. The 
latter cases, if any, were probably not registered in the patient registry even if the VT 
diagnosis was identified by autopsy. These limitations make it likely that there is a small 
underestimation of cases in the original VIP study.
5.1.1.2. SELECTION OF CONTROLS FOR THE VIP STUDY 
The controls were selected from Ullevål hospital in Oslo only while the cases were 
recruited from a broader Norwegian population of young women. Women who gave birth 
at Ullevål hospital differed slightly from the case population; they were slightly older 
(mean 30.7 versus 29.6 years at the time of index pregnancy), of lower parity order,
conceived more often after assisted reproductive technique, had more operative 
deliveries, and had more pregnancy complications in the index pregnancy. Ideally the 
controls should have been selected from the same hospitals as the cases, but this was not 
feasible because of practical and economic reasons. We cannot rule out that this selection 
of controls from one hospital has introduced a selection bias. 
We do not know if our findings only apply to long-term outcomes after pregnancy-related 
VT or if they can be generalized to a broader young female VT population. Therefore, 
another control group consisting of young women with VT not related to pregnancy could 
have provided additional valuable information. The resources in this study did not allow 
us to include another control population. 
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5.1.1.3. SELECTION OF CASES AND CONTROLS FOR PAPER I AND II 
As in most studies based on questionnaires,160 the drop-out rate from the VIP study was 
significant, when the participants were invited to meet for a visit to donate a blood sample 
and to answer a questionnaire in 2006. Of the original study population that comprised 
559 cases and 1229 controls, 531 (94%) of cases and 1092 (89%) of controls were invited 
to participate; some were not invited due to reasons given in Figure 3, however, only 313 
(56%) of cases and 353 (29%) of controls agreed to participate. Hence, we cannot be 
certain whether the cases and controls are representative for the entire population. One of 
the reasons for the large drop-out was probably the inconvenience of having to present at 
the hospital for participation. We had access to the medical records for those participating 
and those who did not, thus to some extent we do know how they differed with regards to 
clinical variables (see Table 8). Participating cases and controls were slightly older, of 
lower parity, fewer were smokers, and they had slightly lower BMI compared to those not 
participating, but the differences were not considered substantial. Moreover, we cannot 
exclude that those who responded did so because they were symptomatic, creating a 
possibility of overestimating PTS.
5.1.2. DATA SOURCES 
5.1.2.1. DATA FROM MEDICAL RECORDS 
All data regarding VT were obtained from the medical records of the participants at the 
hospital where the event took place. As described earlier, these data were validated and 
had thus good quality. An advantage of using medical records as a source of information 
is that a large number of different variables can be collected. We used some of these 
variables for the predictor analyses in paper I. However, the quality of these variables 
may differ since they were collected retrospectively. It is not known whether the 
information regarding weight and height are self-reported or actually measured, and in 
particular self-reported weight can be systematically underestimated.161 Other have 
reported that self-reported weight and height can be relatively accurate.162 However, 
missing values may be high in special weight groups, e.g. obese.162 Smoking at the 
beginning of the index pregnancy may also be underestimated.163 Data regarding delivery 
mode, parity, age, and multiple pregnancies are probably more accurate.  
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Table 8 Distribution of demographic and clinical variables among cases and controls who 
did not or did participate in the questionnaire and blood sample sub-study of the VIP 
study 
Risk factors Cases not 
participating
(n=218)
Cases 
participating
(n= 313)
Controls 
participating
(n=353)
Controls not 
participating
(n= 739)
% % % %
Age (years)
17-24 24.3 15.7 4.8 16.6
25-29 34.4 30.4 26.1 31.7
30-34 23.9 34.2 37.7 29.6
35-54 17.4 19.8 31.4 22.1
Parity
0 52.3 55.9 49.9 49.5
1 26.6 28.8 39.7 29.1
2 12.4 12.5 8.2 14.7
 8.7 2.9 2.3 6.6
Assisted reproduction therapy
Yes 2.8 5.8 2.3 1.5
No 97.2 94.2 97.7 98.5
Cigarettes/day
0 71.1 80.2 90.1 85.0
1-4 3.7 4.5 2.0 4.7
5-9 8.3 6.4 4.5 4.6
10-30 17.0 8.9 3.4 5.7
Immobilization*
Yes 5.0 7.7 0.8 1.1
No 95.0 92.3 99.2 98.9
Body mass index (kg/m2)
missing data 21.6 17.9 7.6 9.2
<25 48.2 55.0 74.5 68.2
25-30 18.3 18.5 11.6 16.0
 11.9 8.6 6.2 6.6
Weight gain (kg)
<7.0 (<10 percentile) 14.2 11.8 8.2 8.4
7-21 (10-90 percentile) 38.1 43.5 38.0 41.0
>21.0 SHUFHQWLOH 47.7 44.7 53.8 50.6
Cesarian section
Yes 32.6 31.0 21.0 19.4
No 67.4 69.0 79.0 80.6
Bleeding  >1000 mL
Yes 13.3 13.4 2.0 4.2
No 86.7 86.6 98.0 95.8
From Bergrem et al.164 (with permission) 
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5.1.2.2. QUESTIONNAIRE DATA 
The whole questionnaire was self-reported, and data were not ascertained by actual 
measures (e.g., weight and height) or by comparison with medical records or registries 
(e.g., parity, income, education, comorbidity, a.o.), and this can lead to inaccuracy and 
measurement bias. For paper II we used questionnaire data only for both the main 
outcome, i.e., the VEINES-QOL/Sym scores, and the different exposure variables. 
However, the main exposure variable VT was captured from the medical records and thus 
considered accurate.
The information regarding socioeconomic variables was collected only once and 3-16 
years after the index pregnancy. It could have been valuable to have this information also 
from the time of index pregnancy to see if some of the variables had changed over time or 
if the differences detected between cases and controls already existed at the time of index 
pregnancy. Cases and controls differed significantly in 2006 regarding education, income, 
and employment. This can be explained by selection bias as controls were not selected 
from the exact same population as cases or the drop-out rate, but may also represent real 
differences between the two groups as low socioeconomic status has been shown to be 
associated with VT.165
5.1.3. ASSESSMENT OF PTS 
There is currently no gold standard for diagnosing PTS. According to the current 
recommendations from ISTH, the Villalta score should be used as the standard diagnostic 
scoring system for PTS in clinical studies.53 When planning the VIP study in 2003-4 there 
was no consensus on how to diagnose PTS, and there were limited number of
publications that had reported use of the Villalta score. For operational reasons, the use of 
a self-reported version of the Villalta score was chosen. 
5.1.3.1. VILLALTA SCORE  
The original Villalta score is not specific for PTS, and symptoms and signs from other 
diseases or previous trauma affecting the lower limbs may also contribute to high scores. 
We are not aware of studies that have applied Villalta score to people without PTS to 
estimate such “back-ground noise”. Hence, PTS frequency according to Villalta score 
may be too high in most studies due to registration of symptoms and signs not related to 
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PTS. Some studies have assessed PTS in the contralateral limb in DVT patients finding a 
Villalta score ш5 in as many as 14-21%.54,59  
The chosen cut-off RISRLQWVRQ WKH9LOODOWDVFRUH WRGLDJQRVH376LVDOVRGHEDWDEOH
and may seem arbitrarily; does a patient with 5 points differ significantly from one with 4 
points? Because there is no gold standard for the diagnosis of PTS, the cut-RIIYDOXHRI
points was chosen using overall interference of venous symptoms and signs with the 
patient’s daily life as well as QOL as surrogate endpoints.63,166 An association between 
Villalta scores and disease specific QOL has also been used for validation,166 but this is 
even more challenging to interpret because the VEINES-QOL/Sym items to a great extent 
overlap with the symptoms and signs that constitute the Villalta score; six of the 11 items 
of the Villalta score are included in VEINES-QOL/Sym.
5.1.3.2. ASSESSMENT OF PTS IN PAPER I 
In paper I we used a self-reported version of the Villalta score for the assessment of PTS. 
The 5 symptom items were scored as in the original score. The 6 clinical signs were self-
assessed instead of by a nurse or physician. Some of the clinical signs may have been 
difficult to understand by the participants, like indurated skin that was explained as 
thickened and hardened skin. We only asked for varicose veins, not for venous ectasia, 
and we asked for pain when using compression stockings, not for pain during calf 
compression. This may have caused the self-reported Vilalta score to diverge from the 
original score, but to which extent or direction is unknown. Ideally the self-reported 
Villalta score should have been validated in a pilot study before used in a large scale 
study.
Our questionnaire left out the question about venous ulcer. A venous ulcer automatically 
categorizes the PTS as severe independent of the total Villalta score,63 thus we may have 
underestimated the frequency of severe PTS in paper I. The probability of having a 
venous ulcer with a Villalta score of 5-15 is, however, very low, as Kahn et al only found 
2 of 147 patients with Villalta scores of 5-15 having a venous ulcer.60   
Another limitation of our PTS assessment is that we lack information regarding the use of 
ECS which may reduce the frequency of PTS after a proximal DVT with 50%.19
Unfortunately, we do not have validated information on recurrent VT either. In the 
questionnaire, 10% of cases with DVT stated that they had experienced more than one 
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event, but we have no information whether these were PEs, or contra- or ipsilateral 
DVTs, and they are not validated. Only ipsilateral DVT has been shown to predict PTS.70  
5.1.4. ASSESSMENT OF QUALITY OF LIFE 
5.1.4.1. GENERIC QOL 
The patient’s experience and opinion are unarguable of great value, but the interpretation 
of patient reported outcomes is difficult. It is recommended to use both a generic and 
disease specific questionnaire in clinical studies reporting on QOL, and inclusion of 
frequently used instruments like SF-36 or EQ-5D may have provided valuable additional 
information to the results in paper II.142,167 Additionally, a generic questionnaire is 
generally accepted for use in healthy controls in contrast to VEINES-QOL/Sym, which
has not been developed for this purpose, nor for patients with a PE or DVT in other 
locations. The SF-36 or EQ-5D are the most commonly used generic questionnaires, and 
results are therefore more easily communicated and can also be compared to population 
norms.  
The two generic QOL measurements used in the VIP study were the Ferrans and Powers 
QOL Index and the General health questionnaire 20. These instruments are not widely
accepted and population norms do not exist. Finally, these scores did not differ between 
cases and controls in our population; and these results were recently accepted for 
publication.168  
5.1.4.2. DISEASE SPECIFIC QUALITY OF LIFE
In paper II the disease specific QOL was assessed by using the VEINES-QOL/Sym 
questionnaire. This is the disease specific QOL measure most frequently utilized in this 
population and it has been found to be reliable and valid.147 It is also validated in 
Norwegian.148 As for the Villalta score, a gold standard does not exist for disease specific 
QOL after DVT which makes validation difficult. The VEINES-QOL/Sym questionnaire 
was modeled after the SF-36.153 SF-36 and the Villalta scores one and four months after 
the acute DVT were used for the validation of VEINES-QOL/Sym, and this may rather 
reflect QOL related to a sub-acute phase and not long-term QOL after suffering a DVT.147
As for several studies,44,145,169,170 we found that the two sub-scores QOL and Sym yielded 
very similar values, and it can be argued that the use of two scores is redundant. I also 
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suspect that the symptoms have a large impact on both the total scores, but that is difficult 
to interpret due to the rather complex calculation of the scores including transformations 
to z- and T-scores. 
Reporting results from one or two items from the questionnaire in addition to the total 
scores could have provided additional information on the impact of the leg problems on 
daily life. One example of such an item is: “Does your leg problem now limit you in these 
daily activities (at work, at home, social or leisure activities when standing for long 
periods, social or leisure activities when sitting for long periods)?” The three possible 
answers are “Yes – limited a lot”, “yes limited a little” and “no, not limited at all.”153  
5.1.4.3. CLINICALLY RELEVANT DIFFERENCES IN VEINES-QOL/SYM 
SCORES 
The developers of the VEINES-QOL/Sym questionnaire have proposed that a difference 
of 3-4 points on either of the two scores can be considered to be of clinical significance to 
the patients.44 This was inferred from the SF-36 questionnaire171 and has not been 
confirmed e.g. by asking the patients if their QOL/ or symptoms were very good, good, 
poor, bad, or very bad and comparing these answers to their actual scores. Hence, it may 
be argued that the clinically relevant differences in VEINES-QOL/Sym scores remain 
unknown. In addition QOL scores often deviate from the normal distribution making it
difficult to analyze them as continuous measures by using the t-test and linear
regression.131 Hence for the analyses in paper II we assumed and defined a clinically 
relevant difference of VEINES-QOL/Sym scores based on the observed percentiles with 
scores <25th percentile representing a reduced outcome DQG VFRUHV 50th percentile 
representing the preferred outcome. This definition was predefined and not an approach 
to find statistically significant results. 
Using the VEINES-QOL/Sym scores as a continuous measure may have made the results 
easier to communicate, as this is the approach used by other authors. The scores in our 
study deviated substantially from the normal distribution and therefore linear regression
could not be applied. Transforming the scores to a more normally distributed scale would 
have been another approach. This would not have solved the problem with defining the 
minimal important difference between scores, but for many QOL scores it has been 
shown that approximately 0.5 x the SD corresponds well with a clinically important 
difference.172,173 This is called a distribution-based method and is based on statistical 
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characteristic of the QOL scores in the actual population.174 Applying this definition to 
our results in paper II, the difference in disease specific QOL and symptoms between 
cases and controls can be considered to represent clinical important differences; the 
differences in mean values were 7.2 and 7.3 and 0.5 x SD among controls were 3.5 and 
3.7, respectively. Whether this approach is valid for the VEINES-QOL/Sym 
questionnaire remains unknown and was not investigated in this thesis. Another way of 
defining the minimal important difference would have been to ask the patients (or some 
of them) if they considered their QOL to be very good, good, bad, or very bad and 
compare these answers to their obtained scores. This is called an anchor-based method.175
5.1.5. MISSING DATA
Missing values in self-reported Villalta and VEINES scores were replaced the same way 
as generally accepted for SF-36. This method is called the half-item rule and missing 
values are replaced with mean of answered values if more than half of the items in the 
questionnaire are correctly completed.176 Different ways of handling the missing values in 
the self-reported Villalta score such as leaving out all scores that were not complete, did 
not change the PTS results, indicating that the obtained scores were robust. We have not 
replaced missing values of demographic variables, but the extent of missing values for the 
different variables are presented in tables of all our reports. Due to missing values the 
number of women taken into the multivariate analysis was reduced and may have 
introduced bias in analysis when adjusting for possible confounders and identifying 
possible predictors.160
5.1.6. LINKING TO THE REGISTRIES 
The attrition from the original VIP study population when linking to the registries was 
low, but as discussed previously, there was a possible selection bias due to selection of 
controls from a slightly different population than cases (from one hospital only). We
consider the introduction of another control group in paper III by using general 
population data of age-matched Norwegian females, in addition to the original controls 
from the VIP study, as an advantage to overcome these potential problems. The 
Norwegian Cause of Death Registry covers all persons registered as inhabitants in 
Norway at time of death and the Cancer Registry of Norway is regarded as high
quality.177 Reporting to these registries is mandatory in Norway. However, causes of 
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death are less accurate,178 and was not the focus of paper III. The main problem in paper 
III may have been some cases who died shortly after a VT outside hospital as these may 
have not been included in the VIP population, leading to an underestimation of the short-
term mortality. Because only five cases died during the first year of follow-up, this bias 
may have had a large impact on the estimates. These missing cases, if any, may have died 
from cancer, leading to underreporting of cancer diagnoses as well. Confounders that 
were not identified could explain the differences in mortality and incidence of cancer 
between cases and controls, but due to the relatively young population and very low 
frequency of comorbidity at the time of VT, such confounders are not easily identified. 
The number of deaths and cases diagnosed with cancer were low, and did not allow us to 
identify any predictors for these outcomes.   
5.2. DISCUSSION OF MAIN FINDINGS 
5.2.1. PAPER I 
5.2.1.1. PTS AFTER PREGNANCY-RELATED DVT 
We found a prevalence of PTS of 42% 3-16 years after pregnancy-related DVT in lower 
limbs. This corresponds well to the small study of Lindhagen et al. from 1986 with a 
mean follow-up of 7 years where 35% of 23 women had clinical deep venous 
insufficiency after DVT during pregnancy or the first week after delivery.92 Clinical deep 
venous insufficiency as defined in Table 5 was a different definition than we used for 
PTS, and the data are therefore not directly comparable. The few other studies on long-
term symptoms and signs in this type of population are also difficult to compare with due 
to their methods of PTS assessment and small samples.93–95  
Our result also corresponds well with the PTS prevalence of 56% in the conventional 
treatment arm of the CaVenT study.20 The DVTs in the CaVenT study were all high 
proximal, similar to the majority of DVTs (83%) in paper I. The participants in the 
CaVenT study were older and had more comorbidity, and only a few had pregnancy-
related DVT. 
5.2.1.2. SELF-REPORTED VILLALTA SCORE AMONG WOMEN WITH NO 
PREVIOUSLY KNOWN DVT 
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Twenty four % of PE cases with no symptoms of DVT at the time of diagnosis and 10% 
of controls had a self-reported Villlalta score of Also PE cases had significantly 
higher scores than controls (P=0.017). Only one study have assessed Villalta scores after 
PE identifying 20% with a score ш5 (compared to 34.2% after symptomatic DVT in the 
same study).179 These findings are very similar to ours. Most PE patients have 
concomitant DVT in a lower limb, even if they are not symptomatic.180 Whether
asymptomatic DVT also leads to PTS remains unknown; only two studies in highly 
selected populations of small sample-sizes have been published.181,182 However, this 
could be a reasonable explanation of our findings. It is not likely that 10% of the controls
KDG'97DIWHULQGH[SUHJQDQF\DVH[SODQDWLRQRIWKHscores in this group; this rather 
corresponds to the fact that self-reported Villalta score and other PTS measurements are 
not necessarily thrombosis specific. As far as we know Villalta scores have not been 
previously reported in healthy controls. 
5.2.1.3. PREDICTORS FOR PTS 
We found that a proximal DVT occurring after delivery was the most important predictor 
for PTS. A proximal DVT is a well established risk factor for PTS, identified in a number 
of studies using different diagnostic methods for PTS. Hence our result corresponds well 
with previous findings.46,47,71,72
Our finding of a postnatal DVT as an independent predictor for PTS compared to an 
antenatal DVT was more surprising. A previous smaller study did not find this 
association, but this may be due to low power since only 95 women were included.93 In 
paper I we have speculated of several possible mechanisms for this association, including
longer duration of LMWH among those having antenatal thrombosis, different 
pathophysiological mechanisms for the development of DVT in the two groups, and a 
delayed diagnosis of DVT after delivery as the focus is shifted towards the newborn baby 
and not the mother anymore. In addition, damage of the vascular endothelium during 
delivery may also contribute to the higher frequency of PTS after postnatal DVT, but 
there is little evidence for any of these explanations in the literature.  
We found a significant interaction between proximal and postnatal DVT as predictors for
PTS; a proximal DVT occurring antenatally was not associated with PTS. This interaction 
was not pre-specified and was not expected. Only 17% (35 women) had a distal DVT, 
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and the statistical power to detect a difference between ante- and postnatal DVT in this 
group was probably too small.
Smoking and age were also identified as predictors for PTS. Age has been associated with 
PTS in other studies, but the mean age in these studies were higher than in our study and 
the results from different studies are conflicting.46,47,51 Smoking has, as far as we know, 
never been evaluated as a predictor for PTS. Possible speculative mechanisms for this 
association, such as increased inflammation among smokers, which might increase the 
risk for PTS, are discussed in paper I.
A recurrent ipsilateral DVT has been associated with the development of PTS in many 
studies,46,56,70 but could not be evaluated in the present study because the lack of
information on recurrence. Recurrences may have contributed to the relatively high 
prevalence of PTS in paper I. 
We did not find an association between high BMI and PTS even if obesity has been 
identified by others as a predictor for PTS.46,47,73 One third of the women in our study 
without missing values for BMI (65/190) were registered in the medical hospital records
with a BMI >25 kg/m2 corresponding to overweight, and this is about the same frequency 
of overweight found in a large Danish cohort of pre-pregnant women.183 In studies 
identifying overweight as a predictor for PTS, about 60-70% of included patients have 
been overweight, and the association with PTS was with BMI >25 kg/m2.46,47,73 The 
present study was not powered to identify an association between obesity, defined as BMI 
>30 kg/m2, and PTS.  
Our findings of a proximal postnatal DVT, higher age, and smoking as predictors for PTS
after pregnancy-related DVT have to be confirmed in other studies, because of 
methodological limitations and the fact that paper I is the first to report on predictors for 
PTS in this population. 
5.2.2. PAPER II 
5.2.2.1. DISEASE SPECIFIC QOL AFTER PREGNANCY-RELATED DVT 
QOL has previously not been evaluated after pregnancy-related VT; nor has VEINES-
QOL/Sym scores been reported for use in healthy controls. Hence our findings cannot be 
compared to other studies. However, the association between previous VT and reduced 
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disease specific and/or generic QOL has been identified by others in general VT 
populations.143,145,150
5.2.2.2. PREDICTORS FOR REDUCED VEINES-QOL/SYM SCORES  
No education beyond high school was identified as a predictor for both reduced disease 
specific QOL and increased symptom burden in paper II. This association has not 
previously been described for VEINES-QOL/Sym scores. Low education has been found
to be associated with poor generic and disease specific QOL in a broad range of 
populations.184–186 Hence, this finding was not unexpected. The reported comorbidity 
among the young female population was low and this can to some extent explain why 
comorbidity was not associated with reduced QOL. Chronic diseases are known to affect 
QOL, but it is not obvious that disease specific QOL should be affected if the comorbidity 
did not involve the lower limbs. The association between high symptom burden from 
lower limbs as assessed by the VEINES-Sym score and marriage/cohabitation is difficult 
to explain, and may represent an incidental finding. 
The presence of PTS has been shown to be an important predictor of reduced QOL in 
several studies.44,142 Both the QOL and the symptom scores of the VEINES-QOL/Sym
questionnaire include symptoms and signs likely to be present in patients with PTS. As 
PTS was found in almost half of the cases, it was not surprising that the VEINES scores 
among cases were lower than for controls. From this follows that PTS could have been 
included in the predictor analyses for reduced QOL in paper II. In paper I (published after 
paper II), we identified that women with a self-UHSRUWHG9LOODOWD VFRUHDIWHU'97 LQ
lower limbs had a significantly lower mean VEINES-QOL score compared to women 
with Villalta scores <5 (see Table 9). These women also had reduced generic QOL 
compared to controls as assessed by the Ferrans and Powers QOL Index indicating that 
both these instruments were sensitive to the presence of PTS.168
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Table 9 Mean VEINES-QOL scores
Group N VEINES-QOL scores,
mean (95% CI) 
Controls 347 52.8 (52.0-53.5)
DVT, no PTS 119 52.6 (51.7-53.5)
DVT, PTS 85 36.2 (33.4-38.9)
DVT, severe PTS 14 23.7 (15.6-31.8)
No PTS: self-reported Villalta score <5; PTS: self-reported 9LOODOWDVFRUHVHYHUH376
self-UHSRUWHG9LOODOWDVFRUH. 
5.2.3. PAPER III 
5.2.3.1. MORTALITY AFTER PREGNANCY-RELATED VT 
We found that the long-term mortality after a pregnancy-related VT was increased
compared to the control group. When comparing to an age-matched Norwegian female 
population we also found an increased mortality the first year after the event, but not the 
years thereafter. We are not aware of other studies assessing short-and long-term 
mortality in this population; but some studies have reported on deaths per delivery.25,26,107
Hence, our findings cannot easily being compared to other studies.  
The case-fatality rates in other VT populations have been reported to be 10-30% after 30 
days and 20-40% after one year.7,104,105 This is much higher than in our population where 
the corresponding case-fatality rates were 0.36% and 0.9%, even when we included 
deaths of all causes and not only VT related deaths. Obviously, one of the explanations 
for this discrepancy is that our population consisted of young, healthy women very 
different from more general or unselected VT populations. Nonetheless, there is probably 
an underreporting of cases dying shortly after a VT, as women with a VT diagnosis 
established after an autopsy is likely to not have been included (see section “5.1.1.1. 
Selection of cases for the VIP study”). Several studies have reported increased mortality 
after VT in more general populations.3,81,103,104
5.2.3.2. CANCER AFTER PREGNANCY-RELATED VT 
It is generally accepted that the risk of cancer is increased after suffering a VT, especially 
the first years.119–122 In paper III we found that cases with a pregnancy-related VT had a 
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higher incidence of cancer after the index pregnancy compared to our control group. This 
difference was not confirmed when comparing the cases with the age-matched Norwegian 
female population during the study years. Due to very few cancer diagnoses, the 
diverging results from these two control groups may be due to lack of statistical power. 
Also, all controls had at least one pregnancy compared with the general Norwegian 
female population where about 12% were childless, hence, the control group may 
represent healthier women who to some extent are protected from cancer as discussed in 
paper III. Another possible explanation is that the controls in the VIP population are not 
representative for the case population due to the fact that they are identified from a 
slightly different population from one hospital only. From this follows that cancer 
diagnosed after a pregnancy-related VT is very rare and screening for cancer in this group 
is probably not justified.
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6. CONCLUSIONS AND FUTURE PERSPECTIVES
The present studies indicate that pregnancy-related, first-time VT has important long-term 
complications in terms of high prevalence of PTS, reduced QOL, increased mortality, and 
possibly increased risk of subsequent cancer. As far as we know long-term outcomes in 
this population have not previously been studied. Despite the methodological concerns 
extensively discussed in this thesis, our work contributes to the scarce knowledge in this 
field. These women, who represent a young and in other ways a healthy population, need 
information and counseling about risk, prevention and treatment of PTS, in addition to
close follow-up from the health care system including VT treatment in accordance with 
guidelines. When involving a proximal DVT, ECS should be worn daily for at least two 
years, and if no risk of bleeding, additional CDT should be considered after delivery. 
There is a need for validation of the self-reported Villalta score and we are currently 
performing such a study. Long-term frequency of recurrent VT has not been assessed 
after pregnancy-related VT and can possibly be done in our VIP study population. Ideally 
a prospective cohort study should be conducted to assess the prevalence of PTS after 
pregnancy-related DVT and identify predictors/biomarkers of importance, but this would 
require a multinational study over many years. To confirm the mortality and incidence of 
cancer in this population and to identify predictors for death an even larger study must be
conducted. A disease specific questionnaire for assessing QOL after PE has been 
developed and the validation of the Norwegian version is ongoing. This questionnaire 
could be used in the women with PE in the VIP study. I plan and hope to contribute to a
number of these research questions. 
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B) VEINES-QOL/SYM QUESTIONNAIRE (NORWEGIAN VERSION)
Besvar hvert spørsmål nedenfor ved å krysse av svaret som angitt. Hvis du er usikker på hva 
du skal svare, vennligst svar etter beste evne. 
Disse spørsmålene er om din oppfatning av beina dine. 
1. I løpet av de 4 siste ukene, hvor ofte har du hatt noen av disse plagene i beina?
(Sett ett kryss på hver linje) 
Daglig Flere 
ganger i 
uka 
Omtrent 
én gang i 
uka 
Sjeldnere 
enn én 
gang i 
uka 
Aldri 
1. Tunge bein 1 2 3 4 5
2. Vondt i beina 1 2 3 4 5
3. Hevelse 1 2 3 4 5
4. Kramper om natta 1 2 3 4 5
5. Varme eller brennende følelse 1 2 3 4 5
6. Urolige bein 1 2 3 4 5
7. Banking 1 2 3 4 5
8. Kløe 1 2 3 4 5
9. Prikking 1 2 3 4 5 
2. Når på dagen er plagene i beina mest uttalte? (Sett ett kryss)
 1 Når jeg våkner  4 Om natta 
 2 Midt på dagen  5 Når som helst i løpet av dagen 
 3 På slutten av dagen  6 Aldri 
3. Sammenlignet med for ett år siden, hvordan vil du vurdere dine plager i beina nå? (Sett
ett kryss) 
 1 Mye bedre nå enn for ett år siden  4 Noe verre nå enn for ett år siden 
 2 Noe bedre nå enn for ett år siden  5 Mye verre nå enn for ett år siden 
 3 Omtrent det samme nå som for ett år 
siden 
 6 Jeg hadde ingen plager i beina i fjor 
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 4. 
 
Følgende spørsmål gjelder daglige aktiviteter. Setter plagene i beina begrensninger for 
dine daglige aktiviteter? Hvis « ja », i hvilken grad? 
  
(Sett ett kryss på hver linje) 
Jeg 
jobber 
ikke 
JA, 
begrenser 
meg mye 
JA, 
begrenser 
meg litt 
NEI, 
begrenser 
meg ikke 
a. Daglige aktiviteter på jobb.  0  1  2  3 
b. Daglige aktiviteter hjemme (husarbeid, småjobber,  
hagearbeid, o.l.) 
 1  2  3 
c. Fritidsaktiviteter hvor du må stå lenge (selskap, ta 
buss, handle o.l.) 
 1  2  3 
d. Fritidsaktiviteter hvor du må sitte lenge (kino, teater, 
på reise o.l.) 
 1  2  3 
 
 
5. 
 
3. I løpet av de 4 siste ukene, har du hatt noen av disse problemene i jobb eller i 
daglige aktiviteter på grunn av plagene i beina? 
 (Sett ett kryss på hver linje) JA NEI 
a. Redusert arbeidstid eller tid til andre aktiviteter  1  2 
b. Gjennomført mindre enn du skulle ønsket  1  2 
c. Blitt begrenset i type jobb eller aktiviteter  1  2 
d. Hatt vanskeligheter med å utføre jobben eller andre 
aktiviteter (f eks det krevde større anstrengelse) 
 1  2 
 
 
6. 
 
I løpet av de 4 siste ukene, i hvilken grad har plagene i beina kommet i veien for 
samvær med familie, venner, naboer eller grupper? (Sett ett kryss) 
 1 Ikke i det hele tatt  4 Ganske stor 
 2  Lett  5 Svær 
 3 Moderat   
 
 
7. 
 
Hvor mye smerter har du hatt i beina i løpet av de 4 siste ukene? (sett ett kryss) 
 1 Ingen  4 Moderat 
 2  Svært lite  5 Mye 
 3 Lite  6 Svært mye 
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8. Disse spørsmålene er om hvordan du føler deg, og om hvordan du har hatt det de
siste 4 ukene som følge av plagene i beina. For hvert spørsmål, kryss av for det
svaret som passer best med hvordan du har følt deg. Hvor mye i løpet av de 4 siste
ukene-
(Sett ett kryss på hver linje) 
Hele 
tiden 
Det 
meste 
av 
tiden 
Ganske 
ofte  
Av 
og til 
Sjelden Aldri 
a. har du vært bekymret for hvordan
beina dine ser ut?
1 2 3 4 5 6
b. har du følt deg irritabel 1 2 3 4 5 6
c. har du følt at du har vært til byrde
for familie eller venner?
1 2 3 4 5 6
d. har du vært bekymret for å
skumpe borti ting?
1 2 3 4 5 6
e. har dine beins utseende påvirket
ditt klesvalg ?
1 2 3 4 5 6
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ERRATUM LIST 
Paper I:
Page 843 in paper I, first paragraph in the result section: Eight cases with a diagnosis of 
both PE and DVT in a lower limb should be included in the 204 with DVT in a lower 
limb. The correct sentence should be: “Eight cases with DVT in the lower limb had a 
symptomatic and objectively confirmed PE at the time of diagnosis; for the analyses these 
were included in the 204 cases with DVT in the lower limb”.
Page 844 in paper I, first paragraph: I have written that “10% of controls had a self-
UHSRUWHG9LOODOWDVFRUHRIUHSUHVHQWLQJVRPHJUDGHRI376”. We have defined PTS as a 
VFRUHRI LQD OLPEZLWKSUHYLRXV'97DQGFRQWUROVKDYHQRWKDG'97DW OHDVWQRW
until delivery in the index pregnancy). The correct had been to leave out the part of the 
sentence that says “representing some grade of PTS”.
Paper II:
Page 1931 in paper II, patients/methods section in the summary: “313 women with 
pregnancy-related DVT” should be replaced with “313 women with pregnancy-related 
VT.” 74 of these 313 cases had PE. 
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